ACTN4 gene amplifications were shown to correlate with pancreatic cancer [113] and could be a potential biomarker for metastatic potency and for predicting the effectiveness of chemoradiotherapy in locally advanced pancreatic cancer [116]. This evidence concerns the gene ACTN4 and pancreatic neoplasm.